Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT).
Jorge Riera-Knorrenschild
No relevant relationships to disclose
Hans-Joachim Schmoll
No relevant relationships to disclose
Dirk Arnold
No relevant relationships to disclose
Hendrik Kroening
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Dieter Nitsche
No relevant relationships to disclose
Reinhard Ziebermayr
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Johannes Andel
No relevant relationships to disclose
Christian Meisel
No relevant relationships to disclose
Manuel Schmidt
Employment or Leadership Position - MOLOGEN
Burghardt Wittig
Consultant or Advisory Role - MOLOGEN
Stock Ownership - MOLOGEN